Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Other Non-current Assets
Long-term assets not reported separately.
Entera Bio Ltd.NASDAQ: ENTX
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 1500.0% from a year ago
Other non-current assets stood at $96K at the end of Q1 FY2026, up 1500.0% from a year earlier and up 206.7% from the prior quarter.
Context
- Other non-current assets amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Other non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +1500.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- (90K) USD
- Year-over-year change
- -1600.0%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (90K) | -1600.0% |
| FY2024 | 2024-12-31 | 6K | +0.0% |
| FY2023 | 2023-12-31 | 6K | +0.0% |
| FY2022 | 2022-12-31 | 6K | -87.0% |
| FY2021 | 2021-12-31 | 46K | — |
Other Non-current Assets vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 other non-current assets of $96K is the 5th highest of the 10 companies compared; the peer median is $83K.
- Its year-over-year change of +1500.0% is the highest of 7, against a peer median of -19.8%.
- Other non-current assets amounts to 0.7% of total assets for ENTX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.32M | -39.6% | +49.6% | 1.6% | |
| Mar 2026 | $2.01M | +1.7% | +43.3% | 4.0% | |
| Mar 2026 | $213K | -80.6% | — | 0.1% | |
| Mar 2026 | $153K | +0.0% | -75.3% | 0.3% | |
| Mar 2026 | $96K | +1500.0% | — | 0.7% | |
| Mar 2026 | $83K | -73.0% | -1.1% | 0.1% | |
| Mar 2026 | $33.77K | — | +594.4% | 0.1% | |
| Mar 2026 | $31K | -0.0% | -85.6% | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ENTX) | $83K | -19.8% | +21.1% | 0.1% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.